{"id":827169,"date":"2025-03-18T16:05:13","date_gmt":"2025-03-18T20:05:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aadi-bioscience-relaunches-as-whitehawk-therapeutics-marking-evolution-into-adc-company\/"},"modified":"2025-03-18T16:05:13","modified_gmt":"2025-03-18T20:05:13","slug":"aadi-bioscience-relaunches-as-whitehawk-therapeutics-marking-evolution-into-adc-company","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aadi-bioscience-relaunches-as-whitehawk-therapeutics-marking-evolution-into-adc-company\/","title":{"rendered":"Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision<\/i>\n <\/p>\n

\n Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets<\/i>\n <\/p>\n

\n Company shares to trade on Nasdaq under the symbol “WHWK” effective\u00a0March 19, 2025<\/i>\n <\/p>\n

\n Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19<\/span> at 8:30 am ET<\/span><\/i>\n <\/p>\n

\n
\n MORRISTOWN, N.J.<\/span>
\n <\/span>, March 18, 2025<\/span><\/span> \/PRNewswire\/ — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as\u00a0Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to Whitehawk Therapeutics, reflecting the Company’s evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision. The Company’s common stock will begin trading under the ticker “WHWK” effective March 19, 2025<\/span>.<\/p>\n

The three assets in the portfolio are in-licensed from WuXi Biologics and utilize HANGZHOU<\/span> DAC’s advanced ADC technology platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The platform is coupled with clinically validated tumor targets that are upregulated in high-potential cancer indications, including lung and ovarian. These assets are engineered to produce minimal off-target toxicity, with a higher therapeutic index and greater stability than first-generation predecessors.<\/p>\n

“Today marks a transformative moment as we reintroduce ourselves as Whitehawk Therapeutics \u2013 a focused oncology company combining science, strategy and execution to swiftly advance our portfolio of promising ADC assets,” said David Lennon<\/span>, President and CEO, Whitehawk Therapeutics. “By leveraging the foundation of well-established tumor biology and integrating cutting-edge technologies, our strategy is designed to address the challenges of treating the most difficult cancers efficiently and effectively. Our goal is to bring all three assets to IND in the next 15 months. Importantly, we believe our robust balance sheet will enable us to see these three assets through early clinical inflections. We are invigorated by the opportunity we have to overcome the limitations of first-generation ADCs to make a meaningful impact for patients.”<\/p>\n

\n Recent Operational Highlights:<\/b>\n <\/p>\n